Cargando…

Rituximab biosimilars open new horizons in immunotherapy

Detalles Bibliográficos
Autor principal:	Jaeger, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703380/ https://www.ncbi.nlm.nih.gov/pubmed/29209531 http://dx.doi.org/10.1136/esmoopen-2017-000234

Ejemplares similares

New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders
por: Lanza, Francesco, et al.
Publicado: (2023)

Cardiothoracic Imaging in China: Opening Up New Horizons
por: Zhang, Long Jiang, et al.
Publicado: (2022)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Biosimilars in ophthalmology: “Is there a big change on the horizon?”
por: Sharma, Ashish, et al.
Publicado: (2018)

New Horizons
por: Dogra, Vikram
Publicado: (2011)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Open New Horizons With the International Journal of Heart Failure for Global Connection
por: Park, Seong-Mi
Publicado: (2022)

New horizons in Biophysics
por: Moylan, Elizabeth C
Publicado: (2011)

New Horizons in Diabetology
por: Tootee, Ali, et al.
Publicado: (2016)

CSCO joins ESMO Open—Cancer Horizons
por: Zielinski, Christoph C, et al.
Publicado: (2016)

ESMO Open—Cancer Horizons and the future of oncology
por: Zielinski, Christoph C
Publicado: (2016)

New STAM, new horizon
por: Yamaguchi, Shu
Publicado: (2016)

New technologies and new horizons
por: Parija, Subhash Chandra
Publicado: (2019)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

Introduction of Biosimilar Rituximab: A Hospital Perspective
por: Cheesman, Simon
Publicado: (2020)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

A new beginning: New horizons
por: Natarajan, Sundaram
Publicado: (2017)

Globalization of Ayurveda: New horizons!
por: Chandola, H. M.
Publicado: (2010)

New Horizon in Advanced Prosthodontics
por: Shin, Sang-Wan
Publicado: (2013)

New Horizon for Neurourological Research
por: Kim, Khae Hawn
Publicado: (2016)

New horizons in geriatric urology
por: Kim, Hyung Jee
Publicado: (2015)

2021: New horizons in neurorehabilitation
por: Muresanu, Dafin
Publicado: (2021)

Neuroparasitology- A New Horizon
por: Parija, Subhash Chandra
Publicado: (2023)

Fermilab opens new horizons
Publicado: (1985)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Sepsis: New horizons
por: Todi, Subhash
Publicado: (2010)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
por: Visser, Jan, et al.
Publicado: (2013)

Introducing pro and con discussions in ESMO Open—Cancer Horizons
por: Zielinski, C., et al.
Publicado: (2022)

A New Publisher, A New Horizon
por: Pimentel-Nunes, Pedro, et al.
Publicado: (2017)

New Horizons for Plant Translational Research
por: Alfred, Jane, et al.
Publicado: (2014)

New Horizons for the Journal of Insect Science
por: Weintraub, Phyllis G
Publicado: (2019)

New light on the horizon of Alzheimer's disease
por: Poo, Mu-ming
Publicado: (2020)

New Horizons in Plant Cell Signaling
por: Wong, Aloysius, et al.
Publicado: (2022)

Immunotherapy in endometrial cancer: new scenarios on the horizon
por: Di Tucci, Chiara, et al.
Publicado: (2019)

Aging and immunotherapies: New horizons for the golden ages
por: Hamilton, Jamie A.G., et al.
Publicado: (2020)

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
por: Uhlig, Till, et al.
Publicado: (2017)

Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
por: da Silva, Antonio, et al.
Publicado: (2014)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
por: Pérez‐Persona, Ernesto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qq2aoi6rpq82h2b6k0nmi5jdvp